Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly known as non-alcoholic fatty liver disease, NAFLD) has become one of the most prevalent chronic liver diseases worldwide, with its incidence continuously rising alongside the epidemic of metabolic disorders. AMP-activated protein kinase (AMPK), as a key regulator of cellular energy metabolism, influences multiple pathological processes associated with MASLD. This review systematically summarizes the regulatory roles of AMPK in lipid metabolism, inflammatory response, cell apoptosis, and fibrosis. Additionally, it discusses the latest developments of AMPK activators from preclinical to clinical studies, while analyzing the major challenges currently faced and potential strategies for resolution. A deeper understanding of AMPK regulatory mechanisms will contribute to the development of more effective therapeutic approaches for MASLD.

MeSH

Liver Diseases, Cells, Non-Alcoholic Fatty Liver Disease, Liver, Immune System Diseases, Research, Therapeutics

Cited by

• Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice. Antioxidants (Basel), 2025
• The Hepatic Axis Fructose-Methylglyoxal-AMPK: Starring or Secondary Role in Chronic Metabolic Disease? J Clin Med, 2025
• A Biochemical View on Intermittent Fasting's Effects on Human Physiology-Not Always a Beneficial Strategy. Biology (Basel), 2025
• Exploration of the correlation between metabolic dysfunction-associated steatotic liver disease and the FAM19A5 factor: A multivariate linear regression analysis. Medicine (Baltimore), 2025